Does sildenafile increase liver enzymes
Reading File
Finding Sources
Searching PubMed
sildenafil hepatotoxicity liver enzymes
Searching the Web
sildenafil liver enzyme elevation hepatotoxicity clinical evidence
Here is a thorough answer on sildenafil and liver enzyme elevation:
Sildenafil and Liver Enzyme Elevation
Short Answer
Yes, sildenafil can cause elevated liver enzymes, but it is considered a rare adverse effect - not a common one. Most users with normal liver function will not experience any hepatic issues.
Mechanism
Sildenafil is almost entirely metabolized in the liver via the CYP3A4 and CYP2C9 enzyme pathways. Its primary metabolite (N-desmethyl sildenafil) is also pharmacologically active. Because the liver is the main site of metabolism, any disruption to hepatic function - or direct drug toxicity - can manifest as elevated transaminases (ALT, AST) or other liver enzymes.
What the Evidence Shows
Frequency: Rare
According to the LiverTox database (NCBI), sildenafil is classified as a rare cause of drug-induced liver injury (DILI):
- At least 5 published case reports of acute liver injury attributed to sildenafil exist.
- No cases of acute hepatic failure have been confirmed.
- The onset typically occurs within 1 to 8 weeks of starting the drug.
Pattern of injury
The liver enzyme pattern has ranged from:
- Hepatocellular - predominantly elevated ALT/AST
- Cholestatic - predominantly elevated alkaline phosphatase (ALP) ± bilirubin
- Mixed - features of both
A notable case involved a 59-year-old man who developed jaundice with ALT 1,665 U/L and AST 1,077 U/L (markedly elevated) after sildenafil use, consistent with cholestatic drug-induced hepatitis.
Clinical features (from published cases)
- Symptoms: fatigue, nausea, right upper quadrant pain, jaundice, pruritus
- Immunoallergic features (eosinophilia on biopsy) have been reported in some cases
- Recovery typically follows drug discontinuation
Herbal/counterfeit products
A number of hepatotoxicity cases have been linked to "herbal" or "natural" aphrodisiac supplements that were found to contain undisclosed sildenafil or other PDE5 inhibitors. This makes it harder to estimate the true incidence from sildenafil alone, as per a review in the European Review of Medical and Pharmacological Sciences.
Official Regulatory Position
- The MHRA and EMA do not list significant liver damage as a common adverse effect based on clinical trial and post-marketing data.
- Abnormal liver function tests are listed as rare events in the official product information.
- The FDA-approved label notes that sildenafil is not recommended in patients with severe hepatic impairment (Child-Pugh C), and dose reduction is required for moderate impairment.
Dosing in Liver Disease
| Hepatic Function | Recommendation |
|---|---|
| Normal | Standard dose (25-100 mg for ED; 20 mg TID for PAH) |
| Mild-Moderate impairment (Child-Pugh A/B) | Reduce starting dose (e.g., 25 mg for ED) |
| Severe impairment (Child-Pugh C) | Avoid / use with extreme caution |
Bottom Line
- Sildenafil rarely causes elevated liver enzymes in people with normal liver function.
- Cases of actual hepatitis (hepatocellular or cholestatic) have been reported but are uncommon.
- The mechanism of hepatotoxicity is not fully established - possibly immune-mediated in some cases.
- Patients with pre-existing liver disease require dose adjustment and closer monitoring.
- If a patient on sildenafil develops jaundice, right upper quadrant pain, or unexplained fatigue, liver enzymes should be checked and the drug discontinued if liver injury is confirmed.
This is a shared conversation. Sign in to Orris to start your own chat.